Investors should keep a close eye on these two dividend stocks in 2026! As interest rates trend downward from their recent peaks, dividend-paying shares are making a comeback this year. Among the notable contenders on my watchlist are Lloyds (LSE: LLOY) and GSK (LSE: GSK).
Both of these companies are well-established dividend payers and have experienced impressive growth in their stock prices, which makes them appealing options for those looking to generate income through their investments.
As of January 9, Lloyds has had a remarkable year, with its stock hovering around 100p, reflecting an astounding 85.5% increase over the past twelve months. The rise in interest rates has positively impacted the company’s earnings from loans, allowing it to return some of that profit to its shareholders.
However, potential investors should be aware of several risks. Unlike global banking giants like HSBC, Lloyds has a strong focus on the UK market. Consequently, a downturn in the housing market or an increase in bad debts could adversely affect profits and future dividend distributions. Additionally, if interest rates continue to decline, the competition for loans may pressure its net interest margin. While there has been some resolution regarding its motor finance controversy, regulatory challenges persist in the banking sector and could significantly influence future payouts.
Meanwhile, GSK is nearing its 52-week high! This company has also seen significant gains, with shares currently priced at 1,882p, just shy of a 52-week peak. Over the last month, GSK's stock has surged by 39.4%, driven by growing confidence in its drug pipeline and reduced concerns about trade tariffs.
GSK is developing new treatments, particularly in areas like hepatitis B and vaccine technology, which are vital for establishing a robust future pipeline of products. This development is critical not only for the company’s revenue but also for sustaining its ability to pay dividends going forward.
That said, the pharmaceutical industry's inherent complexities cannot be overlooked. Drug development is fraught with challenges; clinical trials can fail, regulators can reject applications, and the impending patent expirations of existing products could pose further hurdles later in the decade. If GSK's new drugs do not progress as intended, both profits and dividend growth might stagnate, adversely affecting investor returns.
When examining valuations, I find Lloyds to be reasonably priced rather than a bargain. Its price-to-book (P/B) ratio stands at 1.3, which is comparable to HSBC's 1.4 and NatWest's 1.2, though higher than Barclays' lower ratio of 0.9. In terms of dividend yield, Lloyds offers 3.3%, which aligns closely with its peers or falls slightly below.
On the other hand, GSK provides a dividend yield of approximately 3.4% alongside a price-to-earnings (P/E) ratio of 14.1. This figure is quite favorable compared to AstraZeneca's P/E ratio nearing 32, while remaining consistent with the broader average of the FTSE 100.
In conclusion, both Lloyds and GSK stand out as classic dividend stocks that merit attention from investors in 2026. They offer a combination of reliable income streams, significant recent stock price appreciation, and clear operational strategies, albeit from different sectors.
Nevertheless, it’s important to remember that investment outcomes are never guaranteed. Lloyds is closely tied to the well-being of the UK economy and the performance of its loans, whereas GSK must continue to advance its research and development initiatives effectively. Based on traditional investment metrics, I wouldn’t classify either stock as undervalued. However, they represent solid choices for investors looking to enhance the quality and yield of their portfolios in 2026.
What do you think? Do you agree with this assessment, or do you see potential risks that could outweigh the benefits? Let’s discuss in the comments!
